Jafron Historical Income Statement

300529 Stock

30.38 0.29 0.95%

Historical analysis of Jafron Biomedical income statement accounts such as Selling General Administrative of 363.6 M, Total Revenue of 1.2 B or Operating Income of 528.6 M can show how well Jafron Biomedical Co performed in making a profits. Evaluating Jafron Biomedical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Jafron Biomedical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Jafron Biomedical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jafron Biomedical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Jafron Income Statement Analysis

Jafron Biomedical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Jafron Biomedical shareholders. The income statement also shows Jafron investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Jafron Biomedical Income Statement Chart

At present, Jafron Biomedical's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 528.6 M, whereas Selling General Administrative is forecasted to decline to about 363.6 M.

Selling General Administrative Total Revenue Operating Income Research Development Net Income From Continuing Ops Tax Provision

Total Revenue

Total revenue comprises all receipts Jafron Biomedical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Jafron Biomedical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Jafron Biomedical Co is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Jafron Biomedical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Jafron Biomedical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
Operating Income	1.4B	1.0B	523.2M	528.6M
Total Revenue	2.7B	2.5B	1.9B	1.2B

Operating Income Total Revenue

Jafron Biomedical income statement Correlations

	Selling General Administrative	Total Revenue	Operating Income	Research Development	Cost Of Revenue	Income Before Tax	Income Tax Expense	Gross Profit	Other Operating Expenses	Net Income From Continuing Ops	Ebit	Total Operating Expenses	Total Other Income Expense Net	Net Income	Minority Interest	Tax Provision	Net Interest Income	Interest Income	Ebitda	Reconciled Depreciation
Selling General Administrative		0.98	0.88	0.84	0.99	0.87	0.89	0.95	0.87	0.84	0.86	0.98	-0.51	0.84	0.49	0.84	0.65	0.66	0.93	0.89
Total Revenue	0.98		0.96	0.79	0.98	0.96	0.87	0.99	0.84	0.93	0.85	0.96	-0.52	0.94	0.46	0.93	0.61	0.58	0.95	0.81
Operating Income	0.88	0.96		0.66	0.9	1.0	0.77	0.96	0.74	0.99	0.75	0.85	-0.49	0.99	0.44	0.98	0.5	0.42	0.89	0.63
Research Development	0.84	0.79	0.66		0.85	0.65	0.96	0.83	0.97	0.68	0.97	0.91	-0.58	0.68	0.27	0.7	0.82	0.93	0.86	0.93
Cost Of Revenue	0.99	0.98	0.9	0.85		0.89	0.89	0.96	0.87	0.86	0.88	0.99	-0.52	0.87	0.4	0.87	0.65	0.66	0.95	0.89
Income Before Tax	0.87	0.96	1.0	0.65	0.89		0.76	0.95	0.73	0.99	0.74	0.84	-0.47	0.99	0.45	0.98	0.49	0.41	0.88	0.62
Income Tax Expense	0.89	0.87	0.77	0.96	0.89	0.76		0.9	0.99	0.78	0.99	0.93	-0.59	0.79	0.4	0.82	0.88	0.9	0.93	0.91
Gross Profit	0.95	0.99	0.96	0.83	0.96	0.95	0.9		0.88	0.96	0.89	0.96	-0.58	0.96	0.44	0.96	0.65	0.63	0.97	0.81
Other Operating Expenses	0.87	0.84	0.74	0.97	0.87	0.73	0.99	0.88		0.76	0.99	0.93	-0.61	0.77	0.41	0.8	0.86	0.9	0.93	0.91
Net Income From Continuing Ops	0.84	0.93	0.99	0.68	0.86	0.99	0.78	0.96	0.76		0.77	0.84	-0.52	1.0	0.42	0.99	0.52	0.45	0.89	0.62
Ebit	0.86	0.85	0.75	0.97	0.88	0.74	0.99	0.89	0.99	0.77		0.93	-0.63	0.77	0.36	0.81	0.88	0.91	0.93	0.92
Total Operating Expenses	0.98	0.96	0.85	0.91	0.99	0.84	0.93	0.96	0.93	0.84	0.93		-0.57	0.84	0.42	0.85	0.72	0.75	0.96	0.94
Total Other Income Expense Net	-0.51	-0.52	-0.49	-0.58	-0.52	-0.47	-0.59	-0.58	-0.61	-0.52	-0.63	-0.57		-0.52	-0.12	-0.54	-0.61	-0.56	-0.63	-0.59
Net Income	0.84	0.94	0.99	0.68	0.87	0.99	0.79	0.96	0.77	1.0	0.77	0.84	-0.52		0.42	0.99	0.52	0.46	0.89	0.62
Minority Interest	0.49	0.46	0.44	0.27	0.4	0.45	0.4	0.44	0.41	0.42	0.36	0.42	-0.12	0.42		0.44	0.42	0.24	0.39	0.27
Tax Provision	0.84	0.93	0.98	0.7	0.87	0.98	0.82	0.96	0.8	0.99	0.81	0.85	-0.54	0.99	0.44		0.59	0.51	0.92	0.65
Net Interest Income	0.65	0.61	0.5	0.82	0.65	0.49	0.88	0.65	0.86	0.52	0.88	0.72	-0.61	0.52	0.42	0.59		0.93	0.75	0.78
Interest Income	0.66	0.58	0.42	0.93	0.66	0.41	0.9	0.63	0.9	0.45	0.91	0.75	-0.56	0.46	0.24	0.51	0.93		0.73	0.87
Ebitda	0.93	0.95	0.89	0.86	0.95	0.88	0.93	0.97	0.93	0.89	0.93	0.96	-0.63	0.89	0.39	0.92	0.75	0.73		0.89
Reconciled Depreciation	0.89	0.81	0.63	0.93	0.89	0.62	0.91	0.81	0.91	0.62	0.92	0.94	-0.59	0.62	0.27	0.65	0.78	0.87	0.89

Click cells to compare fundamentals

Jafron Biomedical Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Other Information on Investing in Jafron Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jafron Historical Income Statement

About Jafron Income Statement Analysis

Jafron Biomedical Income Statement Chart

Total Revenue

Operating Income

Tax Provision

Jafron Biomedical income statement Correlations

Jafron Biomedical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Other Information on Investing in Jafron Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Expense	Selling General Administrative
Total Revenue	Operating Income
Research Development	Cost Of Revenue
Income Before Tax	Income Tax Expense
Gross Profit	Other Operating Expenses
Net Income From Continuing Ops	Ebit
Total Operating Expenses	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Minority Interest	Tax Provision
Net Interest Income	Interest Income
Ebitda	Reconciled Depreciation

Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Net Income From Continuing Ops
Cost Of Revenue	+ 0.99	Selling General Administrative
Gross Profit	+ 0.99	Total Revenue
Net Income From Continuing Ops	+ 0.99	Operating Income
Net Income	+ 0.99	Operating Income

Ebitda	- 0.63	Total Other Income Expense Net
Total Other Income Expense Net	- 0.63	Ebit
Net Interest Income	- 0.61	Total Other Income Expense Net
Total Other Income Expense Net	- 0.61	Other Operating Expenses
Reconciled Depreciation	- 0.59	Total Other Income Expense Net
Total Other Income Expense Net	- 0.59	Income Tax Expense